AbbVie (ABBV.US) secures a $1.6 billion collaboration, focusing on molecular glue degraders.

On January 24, AbbVie (ABBV.US) and Neomorph announced a collaboration and license option agreement to co-develop new molecular glues for multiple targets in oncology and immunology. Under the terms of the agreement, Neomorph will receive an upfront payment and is eligible to receive up to $1.64 billion in total option fees and milestone payments, as well as tiered royalties on net sales. Molecular glues are a new class of small molecules designed to selectively target and trigger the degradation of proteins that drive cancer growth or immune system dysregulation, providing more precise therapeutic approaches. Molecular glues have the potential to target proteins historically defined as "undruggable." Insight database shows that in addition to the collaboration with Neomorph, AbbVie has deepened its layout in the fields of neurological diseases and tumors since 2025 through multiple collaborations. This includes expanding its collaboration with AbCellera to develop new TCEs for oncology; collaborating with Simcere on the innovative drug candidate SIM0500 for multiple myeloma; and exercising its option on the first neurodegenerative disease project under its ongoing collaboration with Capsida Biotherapeutics.